Clinical Study

Risk And Protective Factors For Sga-Induced Metabolic Syndrome In Bipolar Youth

Posted Date: May 22, 2018

  • Investigator: Robert Mcnamara
  • Specialties: Adolescent Psychiatry/Psychology, Psychiatry/Psychology, Bipolar Disorder
  • Type of Study: Drug

The first purpose of this study is to identify risk factors associated with developing cardiometabolic symptoms and weight gain after taking Quetiapine. Cardiometabolic risk refers to your chances of developing diabetes, elevated blood lipids, and heart disease. Quetiapine is approved by the United States Food and Drug Administration (FDA) to treat acute manic symptoms in children and adolescents. The second purpose of this study is to see if taking a substance called omega-3 fatty acids can protect against developing cardiometabolic symptoms and weight gain during treatment with quetiapine. Omega-3 fatty acids are not approved by the United States

Criteria:

Your Child Is Being Asked To Take Part In This Research Study Because He/She Is 10 To 17 Years Of Age (Inclusive) And Has Been Diagnosed With Bipolar Disorder, Type I, Manic Or Mixed Episode And Is Taking Or Is Not Taking Quetiapine.

Keywords:

Quetiapine, Adolescent, Bipolar, Seroquel, Omega 3

For More Information:

Lauren Miller
513-558-4112
milleln@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.